SCHEMBL7059451

SCHEMBL7059451

Cc1cccc(NC(=O)Nc2csc(-c3ccc(Br)cn3)n2)n1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.56
GBA1 P04062 10/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
POLB P06746 1/20 0.56
GRM5 P41594 2/20 0.47
NPC1 O15118 8/20 0.47
TP53 P04637 5/20 0.46
MAPT P10636 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
TSHR P16473 3/20 0.46
SORT1 Q99523 2/20 0.46
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
LMNA P02545 1/20 0.43
ALOX15 P16050 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630826 0.79 RAB9A (0.71) RAB9AGBA1MEN1KMT2APOLB
SCHEMBL5338101 0.78 RAB9A (0.53) RAB9AGBA1MEN1KMT2APOLB
SCHEMBL5345140 0.76 CDK5 (0.69) RAB9AGBA1MEN1KMT2APOLB
SCHEMBL14353530 0.73 RAB9A (1.00) RAB9AGBA1MEN1KMT2APOLB
SCHEMBL14558373 0.70 CDK5 (0.53) RAB9AGBA1KMT2APOLBGRM5
SCHEMBL5338684 0.70 CDK5 (0.74) RAB9AMEN1KMT2ANPC1SMN1; SMN2
SCHEMBL14558383 0.69 CDK5 (0.55) RAB9AGRM5NPC1SMN1; SMN2CDK5
SCHEMBL14558360 0.68 CDK5 (0.57) RAB9AMEN1KMT2ANPC1TP53
SCHEMBL7059452 0.68 RAB9A (0.52) RAB9AGBA1MEN1KMT2APOLB
SCHEMBL14558395 0.67 CDK5 (0.53) RAB9AGRM5NPC1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1309589-A2 UREA COMPOUNDS AND METHODS OF USES Amgen Inc. (US) 2003-05-14 EP disclosed
WO-2002014311-A2 UREA COMPOUNDS AND METHODS OF USES AMGEN INC. (US) 2002-02-21 WO disclosed